Cant find any info on who is advising Novartis on the coming spinoff of their generics division Sandoz. Does anyone have a clue? Guess its one of the biggest profile deals of the year in Europe along with DB Schenker.
| +169 | Worlds Worst MDs Competition (2026 Edition) | 27 | 1h |
| +163 | As Lehman people reconvene at UBS, Barclays needs to hire (2023) | 23 | 2d |
| +147 | Who Killed Wall Street | 41 | 44m |
| +98 | Lindsay Clancy - Thoughts from A2 | 21 | 21h |
| +94 | Day at Macquarie | 12 | 3d |
| +53 | How bad did I mess up | 10 | 3d |
| +42 | EB (EVR/CVP/LAZ) vs MBB (Bain/BCG) | 20 | 5h |
| +35 | Misrepresented Houston IB | 14 | 3d |
| +29 | JPM SMALL CAP or WF/JEF/RBC Coverage group | 13 | 2d |
| +26 | Most technical groups? | 14 | 1d |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Probably pjt and bofa in the mix.
Head of healthcare at PJT is former head of m&a at Pfizer
Bofa have done most of the recent large cap deals for novartis.
Pariatur saepe est sunt quo. Minus velit veritatis debitis deserunt libero. Voluptas exercitationem sint cumque dolor eaque recusandae quia.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...